AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

AbbVie (ABBV) Stock: FDA Approves New Parkinson’s Drug Juvmo

Drug approval AI-generated analysis

📈 The FDA approved Juvmo (tavapadon), AbbVie's first selective D1/D5 receptor agonist for Parkinson's disease, distinguishing it from existing D2/D3-targeting therapies.

📊 Clinical data shows 93% of patients maintained stable levodopa dosing after 85 weeks on Juvmo, compared to a worsening trend in the placebo group.

⚡ Patients treated with Juvmo saw a 22-23% improvement in daily living scores versus a 12% decline for the placebo group in the TEMPO trials.

🕒 The drug increased 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours compared to placebo in patients already taking levodopa.

📅 AbbVie confirmed that Juvmo will be available to U.S. patients starting in October 2026, providing a new treatment option for motor symptom control.

⚠️ Common side effects include nausea, headache, and dizziness; dyskinesia and hallucinations were observed when combined with levodopa but the overall safety profile was deemed favorable.

Bullish Signals
  • AbbVie secured FDA approval for Juvmo, a novel once-daily tablet that is the first selective D1/D5 receptor agonist approved for Parkinson's disease.
  • Clinical trials demonstrated that 93% of patients on Juvmo did not need to increase their levodopa dose after 85 weeks, addressing a key limitation of current therapies.
  • The drug showed statistically significant efficacy with a 22-23% improvement in daily living scores compared to a 12% decline in the placebo group.
  • Juvmo extended 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours versus placebo, offering substantial benefits for patients on existing levodopa regimens.
  • AbbVie's Chief Scientific Officer described the approval as a major dopaminergic breakthrough for Parkinson's in decades, validating the strategic value of the asset.
Full Analysis
AbbVie (ABBV) announced that the FDA has approved Juvmo, a new once-daily tablet containing tavapadon for treating Parkinson's disease. This approval marks a significant regulatory milestone as Juvmo is the first and only selective D1/D5 receptor agonist approved for this condition, offering a distinct mechanism of action compared to existing dopamine agonists that primarily target D2/D3 receptors. The drug addresses critical limitations in current Parkinson's therapies by providing an alternative or adjunct treatment to levodopa. Clinical data from the TEMPO trial program indicates that Juvmo can help slow the progression of disease-related complications, such as dyskinesia and motor fluctuations. Specifically, 93% of participants did not require an increase in their levodopa dose after 85 weeks of treatment, compared to a worsening trend in the placebo group. In terms of efficacy, patients taking Juvmo experienced a 22% to 23% improvement in daily living scores relative to baseline, while the placebo group declined by 12%. For those already on levodopa, the drug increased 'on' time by 1.7 hours versus 0.6 hours for placebo and reduced 'off' time by 1.9 hours versus 0.9 hours. AbbVie projects that Juvmo will be available to patients in the U.S. starting in October 2026. The safety profile was described as favorable, with side effects mostly being mild to moderate, including nausea, headache, and dizziness. While dyskinesia and hallucinations were noted as common side effects when combined with levodopa, AbbVie's Chief Scientific Officer characterized this approval as the first major dopaminergic breakthrough for Parkinson's in decades, a sentiment echoed by external experts and patient advocacy groups.